GILEAD SCIENCES, INC. Increase (Decrease) in Equity Securities, FV-NI
GILEAD SCIENCES, INC. (GILD) reported Increase (Decrease) in Equity Securities, FV-NI of $485.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi · last filed 2026-08-06
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2026-06-30 was $343.00M, a 141.55% increase year-over-year.
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2026-03-31 was $142.00M.
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2025-12-31 was $253.00M.
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for the quarter ending 2025-09-30 was $482.00M, a 87.55% increase year-over-year.
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for fiscal 2025 was $451.00M.
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for fiscal 2024 was -$274.00M.
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for fiscal 2023 was -$167.00M.
- GILEAD SCIENCES, INC. increase (decrease) in equity securities, fv-ni for fiscal 2022 was -$657.00M.
| Period end | Increase (Decrease) in Equity Securities, FV-NI 3 month | Increase (Decrease) in Equity Securities, FV-NI 6 month | Increase (Decrease) in Equity Securities, FV-NI 9 month | Increase (Decrease) in Equity Securities, FV-NI 12 month |
|---|---|---|---|---|
| 2026-06-30 | $343.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $485.00M 10-Q · filed 2026-08-06 | $738.00M derived: sum of 3 quarters · filed 2026-08-06 | $1.22B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $142.00M 10-Q · filed 2026-05-07 | $395.00M derived: sum of 2 quarters · filed 2026-05-07 | $877.00M derived: sum of 3 quarters · filed 2026-05-07 | $1.02B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $253.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $735.00M derived: sum of 2 quarters · filed 2026-02-24 | $877.00M derived: sum of 3 quarters · filed 2026-08-06 | $451.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $482.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $624.00M derived: sum of 2 quarters · filed 2026-08-06 | $198.00M 10-Q · filed 2025-11-07 | $72.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $142.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$284.00M 10-Q · filed 2026-08-06 | -$410.00M derived: sum of 3 quarters · filed 2026-08-06 | -$153.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$426.00M 10-Q · filed 2026-05-07 | -$552.00M derived: sum of 2 quarters · filed 2026-05-07 | -$295.00M derived: sum of 3 quarters · filed 2026-05-07 | -$686.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$126.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $131.00M derived: sum of 2 quarters · filed 2026-02-24 | -$260.00M derived: sum of 3 quarters · filed 2026-02-24 | -$274.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $257.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$134.00M derived: sum of 2 quarters · filed 2025-11-07 | -$148.00M 10-Q · filed 2025-11-07 | $41.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$391.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$405.00M 10-Q · filed 2025-08-07 | -$216.00M derived: sum of 3 quarters · filed 2026-02-24 | -$385.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$14.00M 10-Q · filed 2025-05-07 | $175.00M derived: sum of 2 quarters · filed 2026-02-24 | $6.00M derived: sum of 3 quarters · filed 2026-02-24 | $75.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $189.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $20.00M derived: sum of 2 quarters · filed 2026-02-24 | $89.00M derived: sum of 3 quarters · filed 2026-02-24 | -$167.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$169.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$100.00M derived: sum of 2 quarters · filed 2024-11-12 | -$356.00M 10-Q · filed 2024-11-12 | -$417.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $69.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$187.00M 10-Q · filed 2024-08-08 | -$248.00M derived: sum of 3 quarters · filed 2025-02-28 | -$445.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$256.00M 10-Q · filed 2024-05-08 | -$317.00M derived: sum of 2 quarters · filed 2025-02-28 | -$514.00M derived: sum of 3 quarters · filed 2025-02-28 | -$817.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$258.00M derived: sum of 2 quarters · filed 2025-02-28 | -$561.00M derived: sum of 3 quarters · filed 2025-02-28 | -$657.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$197.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$500.00M derived: sum of 2 quarters · filed 2023-11-07 | -$596.00M 10-Q · filed 2023-11-07 | -$539.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | -$303.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$399.00M 10-Q · filed 2023-08-04 | -$342.00M derived: sum of 3 quarters · filed 2024-02-23 | -$484.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | -$96.00M 10-Q · filed 2023-05-03 | -$39.00M derived: sum of 2 quarters · filed 2024-02-23 | -$181.00M derived: sum of 3 quarters · filed 2024-02-23 | -$7.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $57.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$85.00M derived: sum of 2 quarters · filed 2024-02-23 | $89.00M derived: sum of 3 quarters · filed 2024-02-23 | -$610.00M 10-K · filed 2024-02-23 |
| 2021-09-30 | -$142.00M 10-Q · filed 2021-11-03 | $32.00M derived: sum of 2 quarters · filed 2021-11-03 | -$667.00M 10-Q · filed 2022-11-02 | -$935.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $174.00M 10-Q · filed 2021-08-05 | -$525.00M 10-Q · filed 2022-08-08 | -$793.00M derived: sum of 3 quarters · filed 2023-02-22 | -$1.76B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | -$351.00M 10-Q · filed 2022-05-04 | -$967.00M derived: sum of 2 quarters · filed 2023-02-22 | -$1.93B derived: sum of 3 quarters · filed 2023-02-22 | -$1.73B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | -$616.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$1.58B derived: sum of 2 quarters · filed 2023-02-22 | -$1.38B derived: sum of 3 quarters · filed 2023-02-22 | -$1.66B 10-K · filed 2023-02-22 |
| 2020-09-30 | -$964.00M 10-Q · filed 2021-11-03 | -$763.00M derived: sum of 2 quarters · filed 2021-11-03 | -$1.05B 10-Q · filed 2021-11-03 | -$117.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $201.00M 10-Q · filed 2021-08-05 | -$82.00M 10-Q · filed 2021-08-05 | $847.00M derived: sum of 3 quarters · filed 2022-02-23 | $905.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | -$283.00M 10-Q · filed 2021-05-06 | $646.00M derived: sum of 2 quarters · filed 2022-02-23 | $704.00M derived: sum of 3 quarters · filed 2022-02-23 | $761.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $929.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $987.00M derived: sum of 2 quarters · filed 2022-02-23 | $1.04B derived: sum of 3 quarters · filed 2022-02-23 | $1.24B 10-K · filed 2022-02-23 |
| 2019-09-30 | $58.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $115.00M derived: sum of 2 quarters · filed 2020-11-04 | $312.00M 10-Q · filed 2020-11-04 | $278.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $57.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $254.00M 10-Q · filed 2020-08-06 | $220.00M derived: sum of 3 quarters · filed 2021-02-25 | $388.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $197.00M 10-Q · filed 2020-05-06 | $163.00M derived: sum of 2 quarters · filed 2021-02-25 | $331.00M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $134.00M derived: sum of 2 quarters · filed 2021-02-25 | $115.00M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $168.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $149.00M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | -$19.00M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |